PHARMAPACK
Drug Delivery & Packaging

INNOVATION GALLERY eBOOK

2020

Patient / User Safety

Ease of Use

Eco-friendly

Patient Adherence

Cost Effective

#PharmapackEU

For further info please contact salesoperations@informa.com
www.pharmapackeurope.com

informa markets

INDEX

NEW PRODUCTS FROM THE EXHIBITORS

CONNECTED ADD-ON WITH FLOW SENSING TECHNOLOGY FOR MDIS

2020

Company name: Aptar Pharma

Country: Germany

Product name: Connected Add-on with Flow Sensing Technology for MDIs

Product type: Drug delivery device

Date of launch: 30/09/20

Current development phase: Commercialization

Patent: Ongoing

Target markets: Worldwide

Target clients: Pharmaceutical companies

Business model: Direct sales

FACT SHEET

PRODUCT DESCRIPTION

60% of patients fail to take their medication properly, resulting in a significant impact on their health outcomes and overall spend for both Pharmacos and healthcare providers. This connected add-on device, with flow sensing capabilities, tracks the patient's daily medication usage and consumption patterns, supporting the assessment of the efficacy of drug product administration for metered dose inhalers (MDI). The reusable device is attached on the canister of the MDI and detects drug product actuation, effective priming and quality of inspiration by the patient. The device will be CE marked and 510K cleared and its use requires no modification to drug product primary packaging.

APPLICATION AREAS

Designed to help patients with chronic diseases, this connected add-on provides benefits across multiple diseases and therapies, such as helping sufferers of COPD and asthma track their MDI usage and facilitate improved adherence to their prescribed therapy. This device delivers clear benefits for Pharmacos. By utilizing 510(k) and CE clearance, it provides a faster pathway to regulatory approval. Additionally, as the cost of the device can be amortized over multiple uses, the total acquisition cost can be lowered. Feature-rich and easy-to-use, it enables patients to feel more in control of their regimen by also acting as a training and diagnostic tool. Helpful for patients, it also delivers benefits to the healthcare systems, reducing patient training hours and even potentially hospitalizations.

KEY FEATURES (USP)

The smart companion that improves outcomes for patients and increases value for clients. CE marked and 510K cleared, our device fits all canister sizes and requires no modification to drug product primary packaging. This makes the device an easy add-on for pharmaceutical partners, offering a low-touch, high-impact solution that will drive patient adherence and improve outcomes in terms of health, well-being and quality-of-life. Reusable; once the patient has emptied their MDI of medication, they can remove the add-on and attach it to their replacement MDI. This can be done multiple times. The actuation sensor detects time of actuation and coordination with inspiration. The Accelerometer detects priming performance, particularly important for suspensions, and the flow sensor provides feedback on the relative volume and duration of inspiration. Bluetooth enabled, performance is fed back to patients via an easy-to-use App. The data delivered can be used to train patients and provide feedback to doctors – all with greater compliance and better outcomes in mind.

Website: https://pharma.aptar.com/en-us/dispensing-solutions/connected-c-devices.html

INTEVIA 2,25ML

2020

Company name:
BD Medical - Pharmaceutical Systems

Country: France

Product name: Intevia 2,25ml

Product type: Drug delivery Device

Date of launch: to be determined

Current development phase: Prototype

Patent: Ongoing

Target markets: Global

Target clients: Biopharmaceutical companies

FACT SHEET

PRODUCT DESCRIPTION

BD Intevia™2.25 mL is a 2-step push on skin autoinjector that is designed to effectively and safely inject a variety of drugs of different range of viscosities up to 30 cP, with standard 2.25ml 27 G and 29G STW 8 mm needle. It is the only push on skin autoinjector that is designed with proprietary knowledge of primary container process controls, integrating all the functionalities to maximize product performance and allowing to integrate different viscous drugs at different volumes without customisation. This can meet pharmaceutical companies need to have a platform autoinjector for their drugs pipeline.

APPLICATION AREAS

Chronic diseases such as rheumatoid arthritis, multiple sclerosis, etc...

KEY FEATURES (USP)

- Simplifies delivery with two-step, push-on-skin activation
- Provides the convenience and confidence of a robust, patient-friendly design
- Maximum viscosity 30 cP
- Injection time between 5 to 15s
- Visual and audible feedback indicators
- Reliably integrated with BD Neopak™ 8 mm for biotech prefillable syringes
- Right PFS configuration
- Accurate injection time prediction
- Controlled injection depth
- Robust system

Website: https://www.bd.com/en-us/

BD HYLOK™ IV

2020

Company name: BD Medical -Pharmaceutical Systems

Country: France

Product name: BD Hylok™ IV

Product type: Drug delivery Device

Date of launch: 15/04/20

Current development phase: Commercialization

Patent: Patent granted in Russia and Europe (France, Germany, Italy, Spain, Switzerland and UK); Patent pending in China, Japan, India and US

Target markets: Global

Target clients: Pharmaceutical companies

Business model: Direct sales

FACT SHEET

PRODUCT DESCRIPTION

BD HylokTM Safe in your hands in acute situations Innovative glass prefillable syringe designed for IV injected drugs

APPLICATION AREAS

- Intravenous infusion of large volumes of intensive care and emergency drugs
- Contrast media

KEY FEATURES (USP)

BD HylokTM glass prefillable syringe for IV drugs:

- Robust connection with the leading needleless access devices (NLADs)
- Reduced risk of syringe clogging.
- Reduced risk of connectors spontaneous disconnection
- Designed for terminal steam sterilization at 121°C/20 min

Website: https://www.bd.com/en-us/

INJAY

2020

Company name: BIOCORP
Country: France
Product name: INJAY
Product type: Drug delivery Device
Date of launch: 2020
Current development phase: Prototype
Patent: Ongoing
Target markets: Europe, North America
Target clients: Pharmaceutical companies
Business model: Direct sales

FACT SHEET

PRODUCT DESCRIPTION

Injay is the first built-in connected prefilled syringe, based on a custom finger flange (with backstop function) and a custom syringe piston rod with NFC label. Injay collects key information such as injection completed, time and date, type of drug, batch number and expiration date. Information is sent via NFC technology to an app on mobile, tablet or PC.

APPLICATION AREAS

- Clinical trials: Injay can improve the quality, cost efficiency, and statistical significance of the clinical trials thanks to the automatic collection of data, easy transfer to clinical database, and relevant interactions with patients.
- Monitoring of self-administered expensive biologics: can be used to monitor patient treatment adherence and confirm that the product is effectively delivered in accordance with the treatment plan.
- Hospital use: can secure treatment protocol and make sure that the right product has been delivered to the right person at the right time. This could avoid double dosing, missed doses, or inaccurate reporting.
- Vaccination campaigns: can help HCPs maintain detailed and up-to-date vaccination records for each patient and avoid missed or incomplete immunizations

KEY FEATURES (USP)

- Critical information collected: injection fully completed with time and date stamp, key product info such as drug type, concentration, batch, expiry date, syringe ID
- Easy reporting thanks to NFC Technology: transfer of data to a smartphone or specific transmitters, depending on specific use cases and environments (clinical trials, home use, hospital use, remote use)
- Secure usage of the product: backstop mechanism that locks the system after injection and avoid reuse of the same syringe
- Broad compatibility: solution adaptable to all conventional prefilled syringes from 0,5 to 2,25 mL, of different material (glass, plastic, COP...)
- Easy integration into the pharma industrial process, no impact on drug filling process: based on standard components (piston rod, finger flange) assembled as usual by the pharma, does not interfere with the drug, no impact on drug filling process
- Highly cost-effective solution
- Seamless for the users: no modification of traditional user process, ergonomic handling

Website: https://biocorpsys.com/en/nos-produits/dispositifs-connectes/injay/

Demo video: https://vimeo.com/360212318

MICROLITER DOSING SYRINGE (MDS)

2020

Company name: Congruence Medical Solutions LLC

Country: USA

Product Name: Microliter Dosing Syringe (MDS)

Product type: Drug delivery Device

Date of Launch: 31/03/20

Current development phase: Commercialization/ Ready for clinical supply

Patent: PCT/US2017/026684

Target Markets: Worldwide

Target clients: pharmaceutical, biopharmaceutical companies

Business Model: Direct sales, out-licence

FACT SHEET

PRODUCT DESCRIPTION

The Microliter Dosing Syringe (MDS) was conceived to meet an unmet need to provide an accurate, precise microliter dose by incorporating standard prefillable syringe. Accuracy, precision using current prefillable syringes alone is not possible. The MDS is modular to standard prefillable syringe components; this ensures that large investments are not necessary to develop either a custom primary container or to create custom syringe fill-finish infrastructure. The MDS functioning is equivalent to a standard syringe and shown strong user preference in multiple user studies. User-data confirms near-elimination of user-to-user variation with MDS incorporating a 1mL long prefillable syringe. The MDS can be used to deliver accurate precise microliter doses irrespective of whether the drug can is filled in a syringe or in a vial.

APPLICATION AREAS

- Delivery of treatments in ophthalmology, oncology, neurology and dermatology.
- Target treatments include biologics, cell & gene therapy, potent drugs, targeted organ delivery

KEY FEATURES (USP)

- The Microliter Dosing Syringe incorporates standard prefillable syringes (PFS) such as 0.5mL, 1mL Long
- The Microliter Dosing Syringe can deliver accurate and precise volumes in the 5 through 100 microliter range
- The Microliter Dosing Syringe can be made available in prefilled or non-prefilled configurations
- The Microliter Dosing Syringe can also be made available in single, preset dosing or variable dosing configurations
- The Microliter Dosing Syringe requires lower than usual fill volumes, improves batch yield, reduces drug materials costs
- Device performance can help reduce reformulation costs for low dose volumes
- Enables current and emerging therapies challenged with delivering accurate, precise microliter doses

Website: www.congruencemed.com

THE CREDENCE CONNECT™ AUTO-SENSING INJECTION SYSTEM

2020



Company name: Credence MedSystems

Country: USA

Product Name: The Credence Connect™ Auto-Sensing Injection System

Product type: Drug delivery Device

Date of Launch: 03/12/19

Current development phase: Prototype

Patent: Patents Pending

Target Markets: Global

Target clients: Biopharmaceutical companies

Business Model: Direct sales

PHARMAPACK AWARDS WINNER 2020

FACT SHEET

PRODUCT DESCRIPTION

Credence MedSystems introduces the Credence Connect™ Auto-Sensing Injection System, which incorporates automatic real-time monitoring of critical injection data into a reusable ergonomic finger grip. The Connect links to the Credence App on a smart phone and provides a comfortable grip that enhances the usability of any syringe while measuring and transmitting injection progress in real time. The user receives reminders and instructions on the app and can visualize the injection as it occurs, watching a meter increment as the medication is delivered. The user then receives feedback on whether the injection was completed successfully.

APPLICATION AREAS

The self-injection market is growing rapidly as healthcare transfers to the home and yet poor compliance is adversely affecting patient health and the cost of care. Additionally, clinical study data is weakened by a lack of clarity on actual dosing by subjects. The Credence Connect™ enables healthcare providers and self-injecting patients to automatically collect critical injection data and receive real-time feedback on the success of the injection, while improving usability of the syringe. The Connect can be used in clinical studies and commercial applications to facilitate use and drive compliance, improve the integrity of clinical data, characterize patient use patterns and facilitate important communication in the healthcare ecosystem.

KEY FEATURES (USP)

The Credence Connect™ delivers the following unique and valued features:

- Automatic injection monitoring, data transmission and feedback in real time
- Seamlessly captures injection volume, time and duration
- Elegant yet simple method of determining injected volume by measuring plunger rod travel
- Comfortable ergonomic grip to enhance usability of the syringe
- Reusable system to promote sustainability goals & total cost containment
- Open system that is applicable to the Credence Companion® Syringe or any other syringe
- Multiple modes of communication with the user regarding the status of the Connect and the injection
- Captures real-life use patterns that can inform refinement of patient-care models
- Allows confirmation of compliance in clinical trials to inform safety and efficacy assessments
- Enables the proper exchange of information if desired between patients, HCP's, and other members of the ecosystem
- Promotes proper use and improved compliance by providing reminders, instruction, feedback and injection history

Website: www.credencemed.com

SAFE'N'SPRAY™

2020

Company name: NEMERA

Country: France

Product name: Safe'n'Spray™

Product type: Drug delivery Device

Date of launch: 05/11/19

Current development phase: Prototype

Patent: Ongoing

Target markets: Europe, North America in priority

Target clients: Pharmaceutical companies

Business model: Direct sales

PHARMAPACK AWARDS WINNER 2020

FACT SHEET

PRODUCT DESCRIPTION

Safe'n'Spray™: the smart electronic concept device with child resistant and locking features. Safe'n'Spray™ is an integrated device with reusable electronic locking unit and fingerprint identification, to monitor drug delivered and prevent patient from overdosing.

APPLICATION AREAS

"Safe'n'Spray™ responds to specific needs of controlling the doses delivered to patients in a defined period of time, in order to prevent any overdosing. In particular, some drugs such as strong painkillers called opioids (e.g. Fentanyl) can cause respiratory depression in case of overdose, and can be fatal to a child. That's why patients have to rely on a device with locking and child-resistant features for multidose systems, such as Safe'n'Spray™.

Finally, Safe'n'Spray™ is a connected device, with the possibility to send data to e-Nemera cloud system accessible for healthcare professionals (HCP) and patients. This brings added value to the HCP while tracking each time the patient requires a dose, so they can modify the drug concentration or posology as appropriate."

KEY FEATURES (USP)

Safe'n'Spray™ offers a unique possibility to reuse the ""SAFE"" electronic part once the ""SPRAY"" part with the drug is over (eco-friendly on both economic and ecologic sides). The fingerprint sensor for patient unique identification acts as an easy and intuitive child-resistant feature, without the need for adding any secondary packaging with a CR function.

Opposite to fully integrated devices, Safe'n'Spray does not change the manufacturing process of primary packaging on existing filling lines, as another module will deal with assembling Safe'n'Spray™ around primary packaging.

Compared to unit-dose systems for chronic disease, Safe'n'Spray™ appears as a better solution for patients' safety. Indeed, some unit-dose systems (e.g. Instanyl) can come in different pack sizes of 2, 6, 8 up to 10 single-dose containers. Which means a patient could take 10 shots in a row, which is not safe compared to a multi-dose locking system such as Safe'n'Spray™."

Website: https://www.nemera.net/products/ear-nasal-throat/safenspray/

Demo video: https://www.youtube.com/watch?v=ZqgghGFr7rk&t=10s

SMART AUTOINJECTOR

2020

Company name: Phillips-Medisize

Country: Switzerland

Product Name: Smart Autoinjector

Product type: Drug delivery Device

Date of Launch: Supply for Clinical volumes at end of 2021

Current development phase: Commercialization

Patent: Patent Pending

Target Markets: Global

Target clients: Pharmaceutical companies

Business Model: Direct sales

FACT SHEET

PRODUCT DESCRIPTION

The Smart Autoinjector from Phillips-Medisize is a reusable, electronic autoinjector that works with standard 1-2.25ml prefilled syringes. It is small, simple and intuitive for patients, while being powerful and flexible for pharma companies looking to deliver a wider range of formulations (increased volume and viscosity). The Smart Autoinjector provides all the features of current mechanical autoinjectors; full needle safety, two-step injection sequence, intuitive operation. Yet it provides so much more; enhanced user support and feedback, full power throughout the stroke, gentle engagement of the syringe, flexible dosing time. Most importantly though, it significantly reduces environmental waste and provides built-in connectivity.

APPLICATION AREAS

Biologics and peptides dominate new drug applications. Pharmaceutical companies standardize these formulations into 1ml and 2.25ml prefilled syringes. This allows early market entry in standard PFS packaging, while providing a known path to autoinjectors, which offer improved patient convenience and adherence. These devices are the standard in the market.

However, mechanical autoinjectors suffer in three aspects:

- Spring forces are limited and difficult to control
- High environmental impact (plastic waste)
- Difficulty adding Connectivity.

By addressing these shortcomings, while maintaining or reducing cost per injection, the Smart Autoinjector provides an improved solution in all areas where standard autoinjectors are deployed, while extending this range into highly viscous, challenging formulations and greater support for clinical programs.

KEY FEATURES (USP)

The Smart Autoinjector fuses the safety and convenience of single-use disposable autoinjectors with the power, flexibility and reduced environmental impact of electronic reusable devices. This autoinjector has all of the standard features expected from a standard autoinjector:

- 1ml and 2.25ml prefilled syringes with RNS and standard needles.
- Fully needle safe
- Two step, sleeve-triggered injection
- Large viewing window
- Small, convenient size.

Website: www.phillipsmedisize.com

DOSECARE+

2020

Company name: Althena

Country: Italy

Product Name: Dosecare+

Product type: Drug Dosing Device

Date of Launch: 20/08/2020

Current development phase: Commercialization

Patent: Ongoing

Target Markets: EU, North America, middle east, north Africa, Far East, southern East

Target clients: Pharmaceutical companies

Business Model: Direct sales

FACT SHEET

PRODUCT DESCRIPTION

Dosecare+ is the safest and easiest dispensing option for accurate dosing of pharmaceutical liquids. The main feature being the application to adjust and fix the correct volume required for oral liquids, with it's easy to use safety function, a cursor can be positioned and fixed with a 'click of a button'.

APPLICATION AREAS

Dosecare+ administers liquid drugs safely and securely. A solution suited for the oral application of liquid drugs for the disabled, older generations and for children. In all cases where the patients can't receive the right dose by themselves. Dosecare+ has been engineered and designed for carers, hospitals, institutions or for when mothers aren't present to always deliver the same drug dosage. The product is easy to clean, adjust and is a user-friendly safe option for all patients.

KEY FEATURES (USP)

Easy to set, once fixed, the safety feature can't be removed unless intentionally doing so. The withdrawable volume set will always remain consistent. No one is required to check the safety button as it's not possible to remove it unintentionally. Dosecare+ device consists only of three parts allowing it to be easily cleaned, fully adjustable volumes, user-friendly and producible for all sizes 0.5ml to 12.5ml.

Website: www.athena-medical.com

VISIONAIR PLUS

2020

Company name: SGH Healthcaring

Country: France

Product Name: The new ashtma spacer VisionAIR Plus

Product type: Drug delivery Device

Date of Launch: 02/03/20

Current development phase: Commercialization

Patent: Patent pending, France

Target Markets: Worldwide

Target clients: Pharmaceutical companies

Business Model: Direct sales, out-licence, contract manufacturing

FACT SHEET

PRODUCT DESCRIPTION

An innovative asthma spacer specially made for dispensing inhaled treatment. Its new design is user friendly and permits a more comfortable dispensation for the child or for the care giver. And the more important, its efficiency in administering the treatment is higher. This Medical Device Class I minimizes the throat deposit as particles are not sprayed straight towards the mouth.

APPLICATION AREAS

Asthma and respiratory diseases.

KEY FEATURES (USP)

It is made of antistatic material for lesser particles loss and compatible with all MDI on the market. Its enhanced ergonomics allows an easy and intuitive gesture. There is an additional grip that keeps MDI firmly in place for an airtight seal. The large Duck-Bill inhaling valve is designed to minimize inhaling effort and keep normal breathing. Spacer can be used with only one hand allowing the care giver to calm and appease the baby with the other hand. The lateral handle can rotate to keep MDI upright in almost every position, even for small children in a semi-seated or lying position. The handle can be rotated to adapt to both left or right-handed patient. The device can be fully dismantled for easy cleaning and drying.

Demo video: https://www.sgh-healthcaring.com/fr/chambres-dinhalation-visionair-plus/308-grand-masque-adulte.html?adtoken=c87a6dbf4374e130c76f7137f5971ba5&ad=products&id_employee=2&preview=1

ON-BODY DRUG DELIVERY PLATFORM

2020

Company name: Sonceboz SA

Country: Switzerland

Product name: Sonceboz On-Body Drug Delivery Platform

Product type: Drug delivery Device

Date of Launch: 31/10/21

Current development phase: Prototype

Patent: Europe P2078EP00

Target markets: North America, Europe, China, Japan

Target clients: Biopharmaceutical companies

Business model: Direct sales, out-license, contract manufacturing

FACT SHEET

PRODUCT DESCRIPTION

Sonceboz is developing a platform of wearable injection devices intended for use across different use cases ranging from single-container large volume to multi-container drug combination and drug reconstitution therapies. The technology platform is designed to offer pharmaceutical companies unprecedented flexibility and leverage while building upon proven technology and manufacturing processes. In total the Sonceboz platform will offer 5 variations which include, LVI-U and LVI-P for use with cartridges of up to 20mL either user-assembled or prefilled and preloaded, LVI-V for vial transfer of up to 20mL using standard vial-adaptors, ARI for automatic reconstitution and last but not least the DCI which allows different configurations and sequential/ simultaneous injection from 2 cartridge containers for combination therapies.

APPLICATION AREAS

Our device platform will bring value whenever the payload of injected drug exceeds the limits of traditional delivery methods such as autoinjectors or prefilled syringes. We do see a need for such technology in Immunooncology but also in Autoimmune and Rare Disease. Also this innovation allows for programmed and controlled delivery of drug product using electromechanics drive systems which ensure consistent dose delivery.

Our technology allows for:

- controlled large volume delivery of 20mL and more
- controlled drug injection/infusion during clinical trials from one or two containers
- Vial-transfer and injection of 20mL and more
- Automatic-Reconstitution of lyophilized products prior to injection
- Dual-Cartridge applications such as combination therapies

KEY FEATURES (USP)

Our platform in centered around the highly precise Gentle-Touch piston pump which by default comes with 3 ports. This offers a great deal of flexibility such as dual-container and automatic reconstitution options all while leveraging on one architecture. Furthermore, the pump uses vacuum to withdraw the drug product gently from its primary container which is paramount when pumping precious biologic drugs and also because it makes the design independent of the primary container. The latter allows for simple adaptations of the system regardless of type and size of the primary container that is used. Our platform also offers a vial-transfer option (LVI-V) which is highly suitable for use during clinical trials since the device is ready to go and fully program-mable. This allows for streamlined operations during trials where dose accuracy but also adaptability is key.

Website: https://www.sonceboz.com/mechatronics-medtech

WEARABLE DRUG DELIVERY PRODUCT

2020

Company name: Sorrel Medical

Country: Israel

Product name: Sorrel Wearable Drug Delivery Product

Product type: Drug delivery Device

Date of launch: 01/01/22

Current development phase: Functional prototypes and pre-clinical testing

Patent: Ongoing

Target markets: Worldwide

Target clients: Pharmaceutical and Biotech

FACT SHEET

PRODUCT DESCRIPTION

Sorrel Medical is a medical device company focused on the development and manufacturing of pre-filled wearable injectors for easy, efficient self-administration of large volume & high viscosity medications. Sorrel leverages core capabilities & expertise in drug delivery technology development, manufacturing and regulatory experience to offer a robust partner-oriented and patient-centric platform.

APPLICATION AREAS

Medication-dependent

KEY FEATURES (USP)

- Accurate and controlled pumping mechanism
- Primary container agnostic; vials or cartridges
- Pre-filled and pre-loaded
- Smart sensing capabilities
- Connected

Website: www.sorrelmedical.com

APPLICATOR CAP 2IN1 APPLISIL

2020

Company name: UNION PLASTIC

Country: France

Product name: Applicator Cap 2in1 APPLISIL

Product type: Drug delivery Device

Date of launch: 06/02/19

Current development phase: Prototype

Patent: FRANCE: 3047474

Target markets: Europe, Germany, Russia, North America, Brazil, India

Target clients: Pharmaceutical companies

Business model: Direct sales

FACT SHEET

PRODUCT DESCRIPTION

The applicator cap 2in1 APPLISIL® is a cap for vaginal cream tubes facilitating the clipping of a vaginal applicator for dosing and administering the cream. The innovation lies in its design which avoids the direct contact of an applicator with the tip of the aluminium tube. The main advantages of this solution are the reduced emission of aluminium or plastic particles (by eliminating the process of screwing the applicator into the aluminium thread) and the optimization of the clipping of the applicator (by dimensioning a perfectly adapted cap). Thanks to the solution 2in1 APPLISIL®, the user experience is improved, the hygiene is intensified, the dosage is facilitated and women's health preserved.

APPLICATION AREAS

PREVENTIVE & CURATIVE treatments WOMEN'S HEALTH:
Vaginal administration for rebalancing, moisturizing, contraceptive, lubricating or procreative use.

HUMAN AND ANIMAL HEALTH:
Widening of the concept of cream dosing for external administration as anti-infective, antibacterial, anti-inflammatory, pain-killer and other purposes, as an alternative to unclear pump vials and un-environmentally friendly single dose tubes.

KEY FEATURES (USP)

ERGONOMIC

- The cap opens and closes with a simple clipping operation
- The vaginal applicator fits perfectly to the cap by simply clipping
- The applicator is firmly maintained during dosing HYGIENIC
- The vaginal applicator is no longer in direct contact with the aluminium tube SAFETY
- The emission of aluminium or plastic particles in the cream is avoided INTERFACE
- For aluminium tube with M9 thread
- Designed to fit our large range of APPLISIL vaginal applicators for dosing 0.5ml, 1ml, 1.5ml, 2ml, 2.5ml and 5ml. GALENIC FORM
- Dosage of cream, gel and semi-solid solution

Website: www.union-plastic.com

SMARTDOSE® GEN. II 10ML DRUG DELIVERY PLATFORM

2020

Company name: West Pharmaceutical Services, Inc.

Country: Ireland

Product Name: SmartDose® Gen. II 10mL Drug Delivery Platform

Product type: Drug delivery Device

Date of Launch: 07/02/19

Current development phase: Prototype

Patent: Ongoing

Target Markets: North America, Europe and Japan

Target clients: Biopharmaceutical companies

Business Model: Direct sales

FACT SHEET

PRODUCT DESCRIPTION

Advances in therapeutic proteins have helped to create new and more targeted drug products for a variety of issues. However, higher viscosities may not allow for conventional delivery due to the need for longer injection times to reduce patient discomfort. The SmartDose® Generation II (Gen. II) drug delivery platform leverages the success of our Gen. I device with proven engineering and industrialization on a larger scale. With a dose volume of up to 10mL, the SmartDose Gen. II device can adapt to a variety of drug delivery needs.

APPLICATION AREAS

Delivery rates for the SmartDose Gen. II 10mL device are pre-programmable, and high viscosities can be handled through adaptive technology for large dose volumes. The device supports user-loaded subcutaneous (SC) self-administration, which promotes pain-tolerant, less frequent larger-volume injections. SC administration is particularly beneficial for long-term or chronic drug treatments, as it helps patients to avoid repeat hospital visits. While biologics provide life-saving advanced therapies to patients, there is an increasing list of demands these medications place on drug developers. In a price-sensitive, patient-centric world, value has never been more necessary. West empowers its partners with the SmartDose Gen. II 10mL device to navigate challenges found along the drug development road, improve patient outcomes and provide better return on investment.

KEY FEATURES (USP)

Driven by extensive human factors testing and user requirements analysis, the SmartDose® Gen. II 10mL device is a patient-centric wearable injector that enables patients to self-administer medication through an optimized user experience that incorporates an intuitive interface, streamlined workflow and enhanced ergonomics. Visual, tactile and audible feedback helps to boost user confidence. All versions of the SmartDose platform adhere to the patient's body, usually on the abdomen, so patients can be hands-free during administration. An integrated solution for the containment and delivery of injectable medications, the SmartDose Gen. II 10mL device features a FluroTec® barrier film coated piston and a silicone-free Crystal Zenith® cartridge. The cartridge is made from Daikyo Seiko, Ltd.'s proprietary cyclic olefin polymer, which provides design flexibility for unique biologic requirements. The cartridge elastomer components are processed and sterilized to ensure a high level of quality and safety for patients.

Website & Demo video: https://www.westpharma.com/products/self-injection-platforms/smartdose/smartdose-gen-II

SMARTPILOT™ FOR YPSOMATE®

2020



Company name: YPSOMED

Country: Switzerland

Product name: SmartPilot™ for YpsoMate®

Product type: Drug delivery Device

Date of launch: 22/10/19

Current development phase: Prototype

Patent: EP19172037.4; WO 2018064784 A1; WO 2018085952 A1; WO 2019087001 A1; WO 2019086992 A1; WO 2019159035 A1; EP 3539593 A1; EP 3545993 A1; EP 3545992 A1; EP 3545991

Target markets: North America, Europe

Target clients: Biopharmaceutical companies

Business model: Manufacturing and licensing of proprietary Ypsomed platform technology with biopharmaceutical firms

FACT SHEET

PRODUCT DESCRIPTION

Connected drug delivery systems are making fast market inroads to boost therapy adherence and support the self-management of chronic diseases. SmartPilot™ for YpsoMate® reflects a reusable connected add-on that transforms the proven 2-step autoinjector YpsoMate® into a cloud-connected system. SmartPilot™ comes with two sets of key functionalities: One monitors device usage and makes available the therapy-relevant injection data to providers or caregivers. The other guides patients step-by-step through the drug administration process including authentication of the self-injection device or advice on holding time. The sensor was developed such that the YpsoMate® autoinjector is compatible with SmartPilot™ without any further modification.

APPLICATION AREAS

SmartPilot™ for YpsoMate® has been successfully user-tested and proven to simplify the safe and effective repeated self-injection of medicine across chronic disease areas, such as hypercholesterolemia, diabetes, asthma or rheumatoid arthritis. Outcome-based payment systems, real-time therapy monitoring, and patient convenience are driving forces to develop digital solutions that accelerate drug product market uptake. Given that SmartPilot™ does not require any physical modification to YpsoMate®, it can be flexibly introduced as part of product life-cycle post market introduction. Moreover, SmartPilot™ for YpsoMate® also contributes to simplify and improve medication adherence in clinical trials. SmartPilot™ enables the safe and effective self-administration of investigational drugs, facilitates complete remote patient monitoring, and improves the quality and integrity of adherence data collected in multi-site clinical trials.

KEY FEATURES (USP)

- Wireless tracking of injection date, time and success using fully encrypted Bluetooth® protocol
- Advanced real-time patient guidance throughout the injection process including advise on holding time
- Direct visual and audible feedback on the SmartPilot™ add-on locally or the remote real-time display of the instructions for use on a companion mobile app
- Authentication of the combination product at the point-of-use: NFC-based smart label identification of combination product to increase patient safety (e.g. expiry date, product strength, recalls)
- As basis for more advanced adherence management systems (e.g. reminders or notification system).
- Not requiring any physical modification to YpsoMate® core mechanics. The same autoinjector configuration can be flexibly used with or without SmartPilot™ (e.g. life-cycle management)
- Lifetime energy management concept eliminating the need to charge SmartPilot™ during its in-use time
- Integrated with the Ypsomed device management solution YDS SmartServices™ that provides a secure end-to-end smart device system

Website: https://yds.ypsomed.com/en/injection-systems/smart-devices/smartpilot.html

NEOFLEX PLUNGERS

2020

Company name: Datwyler

Country: Belgium

Product name: NeoFlex plungers

Product type: Primary Packaging

Date of launch: 04/02/20

Current development phase: Commercialization

Patent: Ongoing

Target markets: Worldwide

Target clients: pharmaceutical companies, biopharmaceutical companies, CMO/CDMO, distributors

Business model: Direct sales

Product photo: not available

FACT SHEET

PRODUCT DESCRIPTION

The NeoFlex plunger is a fully fluoropolymer coated plunger which offers a robust packaging solution for the prefilled syringe and cartridge markets. This product meets the rising demands related to biological drugs and self-administration with drug delivery devices. In terms of cleanliness of the product and the functional performance, this plunger is a perfect alternative to the film coated plungers already available in the market. The rubber and coating are identical to the OmniFlex plungers from Datwyler and complete the platform of coated products. The plungers are currently available in 0,5 to 3 ml for prefilled syringes and 3 ml for cartridges and can be delivered in Ready-to-Sterilize or Ready-to-Use format packed in standard bags or Rapid Transfer Port bags.

APPLICATION AREAS

- Long term storage of highly sensitive large molecule drugs
- Prefilled syringes for manual application
- Prefilled syringes in auto-injector
- Cartridges in pen-injectors
- Siliconized glass and polymer syringes

KEY FEATURES (USP)

- Excellent extractable and leachable profile
- Compatible with gamma and steam sterilisation
- Fully coated plunger with guaranteed container closure integrity
- Consistent break loose and gliding forces
- Limited plunger movement during air transport
- Low particle levels
- Offered with 100 % camera inspection
- Operates on standard filling lines

Website: https://sealing.datwyler.com/industry-solutions/health-care.html

PUSH TAB® LOOP

2020

Company name: Huhtamaki Flexible Packaging Germany GmbH & Co. KG

Country: Germany

Product name: Push Tab® loop

Product type: Primary Packaging

Date of launch: 01/05/19

Current development phase: Commercialization

Patent: Pending

Target markets: Worldwide

Target clients: Pharmaceutical companies

Business model: Direct sales

PHARMAPACK AWARDS WINNER 2020

FACT SHEET

PRODUCT DESCRIPTION

Push Tab® is an alternative opening for strip packaging. With Push Tab® loop Huhtamaki is offering a recyclable tablet packaging solution. The material is completely without PVC and makes it easy to remove tablets simply by applying pressure. The barrier properties are not affected by the push through feature of the film and guarantee the highest levels of product safety.

The risk of migration is also very low, as an extrusion-laminated and coated laminate that doesn't contain any solvents is used. Different versions and forms ensure adequate market differentiation and are sustainable alternatives to blister or cold-form applications.

APPLICATION AREAS

The topic of sustainability in packaging is reaching the pharmaceutical market. As an recyclable alternative to blister and cold-form, Huhtamaki Push Tab® loop is a frontrunner in sustainable packaging solutions for pharmaceutical single dosage solids.

KEY FEATURES (USP)

Push Tab® loop is made from recyclable polyolefin laminate. More than 90 percent of the components which are used belong to the same material class (PE and PP). The result is a primary packaging recycling rate of better than 70 percent in an existing and proven recycling process.

Additionally, by a significant reduction of the material consumption, Push Tab® loop offers cost saving potential in comparison to blister and cold form.

Website: https://www.huhtamaki.com/en/pushtab

ACTIVEGUARD® CONNECT™

2020

Company name: LOG - Pharma Primary Packaging
Country: Israel
Product name: ActiveGuard® Connect™
Product type: Primary Packaging
Date of launch: 05/11/19
Current development phase: Prototype
Patent: Pending
Target markets: Worldwide
Target clients: Pharmaceutical companies
Business model: Direct sales

FACT SHEET

PRODUCT DESCRIPTION

LOG's ActiveGuard® Connect™ provides the pharma and nutraceutical industries a smart packaging solution which drives adherence, enables Big Data analysis and provides manufacturers with a unique connection to engage with the end-customer and build a long-term relationship. ActiveGuard® CONNECT™ features a smart IoT component with integrated desiccant chamber which is inserted into the neck of a bottle and links the packaging to the patient's smartphone. The smart packaging product enables indication of taken doses, tracks temperature within the bottle, and can remind or alert patients as needed to drive adherence.

APPLICATION AREAS

- Supports the patient to follow his prescribed drug regimen
- Empowers pharma and nutraceutical manufacturers to improve medication and supplement efficiency.
- Enables the pharma or nutraceutical manufacturing to engage with the patient and build a long-term relationship
- Helps to monitor the patient's drug compliance/adherence during clinical trials / studies.

KEY FEATURES (USP)

ActiveGuard® Connect™ is a smart IoT component with an integrated desiccant chamber which is inserted into the neck of a bottle:

- It links the packaging via Bluetooth to the patient's smartphone providing the manufacturer a unique connection to engage directly with the end user / patient.
- Enables indication of taken doses, tracks temperature within the bottle, and can remind or alert patients as needed to drive adherence.
- Presents compliance-data on a dashboard for analytical and monitoring purposes during clinical trials. Empowers pharma and nutraceutical manufacturers to improve medication and supplement efficiency using Big-Data analysis

Website & Demo Video: https://logpac.com/smart-packaging-activeguard-connect

QUARTZ VIAL

2020

Company name: NEXUS COMPANY INC.

Country: Japan

Product Name: Quartz Vial

Product type: Primary Packaging

Date of launch: 01/11/18

Current development phase: Commercialization

Patent: Ongoing

Target markets: Europe & North America

Target clients: Biopharmaceutical companies

Business model: Direct Sales

FACT SHEET

PRODUCT DESCRIPTION

Quartz - very new material for Vials! Free from Delamination, Flakes, Alkali elution and PH-shift! Our Vials are made from Pure Quartz. It is different from Borosilicate glass, neither plastic. So, the risk of Delamination, Flakes, Alkali elution and PH-shift can be eliminated. Quartz can give you great possibilities!

APPLICATION AREAS

Primary packaging for Biopharmaceutical.

KEY FEATURES (USP)

In the current Vial market, “Glass” and “Plastic” are main materials, which face critical problems of Delamination, Flakes, Alkali elution and PH-shift. However, our Vial is made from Pure Quartz (SiO2100%) so there is no concerns for such problems.

Website: https://www.kyoto-nexus.com/sekiei_en/

POURER “LOTUS”

2020

Company name: PACKSYS GmbH
Country: Germany
Product name: Pourer “Lotus”
Product type: Primary Packaging
Date of launch: 15/10/20
Current development phase: Prototype
Patent: None
Target markets: Europe
Target clients: Pharmaceutical companies
Business model: Direct sales

PHARMAPACK AWARDS WINNER 2020

FACT SHEET

PRODUCT DESCRIPTION

Among the dosage forms of medications, liquids are only a small sector compared to tablets or capsules. But there are some benefits like the faster effect after taking or the possibility of very simple individual dosing. Besides, liquids are much easier to swallow. But without a good packaging, taking liquids can be frustrating. Everybody knows it, you need liquid medication like cough syrup or dietary supplement and there’s no way to pour it out without spilling. PACKSYS thought about these problems and created the new pourer called “Lotus”, which combines several benefits in one closure: one piece system, tamper-evident, flip-top closure and one hand operation.

APPLICATION AREAS

If you need liquid medication like cough syrup or dietary supplement and there’s no way to pour it out without spilling. The bottle thread is wet after using and should be cleaned before closing the bottle. Otherwise sugar-containing liquids will cause adhesion between bottle and closure after drying. Opening the bottle gets more and more difficult. Little better than syrups are oils for example for skin care. They are always easy to open – actually too easy – but after a short period of time the whole bottle is oily, prints on the bottle dissolve or labels peel away. And wherever the bottle stood, oily rings are left behind. Lotus pours out liquids with different viscosity without spilling - regardless whether you pour out fast or very slow. At PACKSYS we tested Lotus with different kind of oils, syrups, very thick fruit juices and alcoholic blends for sauna therapy.

KEY FEATURES (USP)

First, the pourer is made out of pharma grade material and is therefore suitable for both, pharma and food products. With the PP28 thread it fits on a wide range of standard bottles in glass or plastics like PE, PP or PET. The pourer “Lotus” is only one piece. This requires a very intelligent tool concept. It was important for us to produce the pourer in mono-material for recycling reasons. Comparable products are assembled components in different materials and therefore not recyclable. “Lotus” is a tamper evident closure with protection between bottle and closure and a small seal on the flip-top lid, which only breaks when first used. The flip-top lid is very easy to open, even with only one hand. “Lotus” pours out liquids with different viscosity without spilling - regardless whether you pour out fast or very slow. With an elegant and timeless design “Lotus” fits to a wide range of bottle shapes.

Website & Demo Video: https://packsys.de/en/innovation/pourer-lotus/

TABTEC CR

2020

Company name: Sanner GmbH

Country: Germany

Product name: TabTec CR

Product type: Primary Packaging

Date of launch: 05/11/19

Current development phase: Commercialization

Patent: Europe: EP 2945 875 A1, USA: US 2015 0344 202 A1 in pending

Target markets: Europe, North America, Asia

Target clients: Pharmaceutical companies

Business model: Direct sales

FACT SHEET

PRODUCT DESCRIPTION

The TabTec CR is a pharmaceutical packaging for solid drugs with a novel child-resistant function. The Press & Flip child safety mechanism in the closure prevents accidental opening. The integrated desiccant and the appropriate color selection also protect them from moisture and light at all times. The integrated pouring assistance offers a particularly hygienic and simple dosage of the medicines. In an independent consumer study, the novel and reliable child-resistant packaging for tablets was given an excellent rating, in comparison to child-resistant blister packs, especially concerning the child-resistant opening mechanism, the hygienic removal and easy use on the go.

APPLICATION AREAS

The TabTec CR is a child-resistant pharmaceutical packaging for solid drugs (tablets, logenzes, drops and capsules), especially for pharmaceuticals that pose health hazards when misused by children and which require childproof. These are drugs like painkillers (for e.g. headaches, joint pain, etc.), antidepressants, sedatives, iron supplements, or medical cannabis. It has a modern and flat design which makes it an ideal “On-The-Go Packaging” and for consumers very convenient while travelling, working or in leisure time.

KEY FEATURES (USP)

The TabTec CR is unique, unmistakable and child proof right down to the last tablet. The new Press & Flip child safety mechanism offers a reliable child safety function. But even the Tab Tec CR is child-proof, it is easy to open for elderly and/or people with motor impairments, thanks to the negligible amount of force required. Contents stay safely packed, dry, and hygienic at all times, including a hygienic tablet removal, due to the integrated opening for dispensing. No separate capsules or packets are necessary due to the integrated desiccant because of the integrated opening for dispensing. Its slim, rounded shape fits in any pants/shirt pocket and can be taken anywhere. The innovative design stands out from the crowd and consumers associate the brand owner with modernity and innovation. An easy and cost-effective warranty function can be implemented. TabTec CR meets relevant regulatory requirements for pharmaceutical packaging

Website: https://www.sanner-group.com/en/pharmaceutical-packaging-from-the-market-leader/child-proof-pharmaceutical-packaging/

Demo video: https://www.youtube.com/watch?v=A-ax5kqLrI0&feature=youtu.be

SCHOTT IQ®

2020

Company name: SCHOTT AG

Country: Germany

Product name: SCHOTT iQ®

Product type: Primary Packaging

Date of launch: 05/11/19

Current development phase: Commercialization

Patent: >130 Patents

Target markets: Mainly high-value drugs, such as biologics, cell and gene therapies, worldwide.

Target clients: Pharmaceutical companies

Business model: Direct sales

FACT SHEET

PRODUCT DESCRIPTION

The global pharma industry is going through a significant transformation from blockbuster drugs to personalized medicine. Hence, pharma companies are looking for ready-to-use (RTU) containers, which allow to outsource “non-core” activities for more flexibility in manufacturing. The holistic SCHOTT iQ® platform takes RTU to the next level by standardizing a versatile portfolio of RTU syringes, vials and cartridges within a single tub format to run on one filling line. Pharma manufacturers can thus fill various drug/container configurations on the same line reducing changeover times. SCHOTT iQ® is compatible with numerous leading and upcoming machine vendors and includes pre-validated container/elastomer combinations.

APPLICATION AREAS

Over the past years, the number of blockbuster drugs in the development pipeline has decreased, while the number of biopharmaceuticals and other small-batch drugs has increased. This has put pressure on pharmaceutical companies to find flexible ways to fill small batches and/or different containers for different markets. Hence, pharma companies are looking to out-source process steps such siliconization, depyrogenation and sterilization. With RTU, these steps are handled by the primary packaging supplier, thereby leaving pharma companies with fewer process steps and lower total cost of ownership. Therefore, the SCHOTT iQ® platform aims to help pharmaceutical companies retain flexibility in response to rapidly changing market conditions and demand, while ensuring patient safety with high quality ready-to-use containers

KEY FEATURES (USP)

The SCHOTT iQ® platform based on the PFS standard (ISO 11040-7) was designed to:

- Maximize flexibility with a versatile portfolio of pre-validated and flexible RTU container/elastomer systems to match a broad range of filling machines. The container portfolio includes the new extension of adaptiQ® ready-to-use vials, cartriQ™ ready-to-use cartridges and syriQ® prefillable syringes featuring the award-winning syriQ BioPure® silicone free syringes.
- Reduce complexity by standardizing packaging, which speeds up installation and qualification times, reducing manufacturers’ time to market.
- Enhance patient safety with the highest quality containers made of FIOLAX® type I glass.

Website: https://microsites.schott.com/iq/english/index.html

Demo video: https://www.youtube.com/watch?v=k9vdsI4UUUg&feature=youtu.be

RUSSIA CRYPTO-CODE LABELS

2020

Company name: Bähren Druck

Country: Germany

Product name: Russia Crypto-Code Labels

Product type: Secondary Packaging

Date of launch: 01/11/19

Current development phase: Commercialization

Patent: None

Target markets: Europe

Target clients: Pharmaceutical companies

Business model: Direct sales

FACT SHEET

PRODUCT DESCRIPTION

With the entry into force of the Russian Federal Law No. 488-FZ, crypto-serialization in Russia is mandatory from January 2020. The so-called crypto code is characterized by the necessary cryptographic component consisting of 44 character sets. GTIN, serial number and company information are further required code contents. These four elements double the data set to be encoded in a datamatrix code compared to EU serialization and thus require a larger and more complex datamatrix code. This crypto code places high demands on the technical implementation of inline printing. The challenges are solved by using pre-printed crypto labels.

APPLICATION AREAS

With the entry into force of the Russian Federal Law No. 488-FZ, crypto-serialization in Russia is mandatory from January 2020. The use of pre-serialized crypto code labels allows the pharma companies to outsource complex serialization processes to Bähren Druck. Of course, the order of pre-serialized crypto labels requires a clear agreement between the pharma company and Bähren Druck. Main questions relating to the serial number, data interfaces, and reporting are important tasks which will be defined in the onboarding process.

KEY FEATURES (USP)

The Russian implementation requires cryptographic code contents in addition to the usual serialization code contents GTIN (01) and serial number (21). This includes four digit company information (91) and a 44-digit variable cryptographic number (92). The coding of the data content requires a large datamatrix code size of 36 x 36. (For comparison: EU serialization requires a 26 x 26 data matrix code.) This datamatrix code size challenging the widespread inline serialization in the packaging line. Here are difficult frameworks during the print process: Vibrations, different materials surfaces and qualities, curvature of cardboard flaps and other sensitive setting parameters of the line equipment. The use of pre-serialized crypto labels solves these challenges. This includes the encoding of the data according to GS1 standard with the use of the application identifier (01), (21), (91) and (92). The printing of the demanding datamatrix-code and human readable text. As well as the print-verification and the compliance according to the required print quality. This enables pharmaceutical companies to minimize set-up time in their packaging area, maintain machine speed and minimize the risk of rejecting faulty products. At the same time, investments in hardware and software updates as well as new processes and training in dealing with the complex issue are eliminated.

Website: www.your-special-case.com

SYRINGELOK™

2020

Company name: Nordson Medical
Country: USA
Product name: SyringeLok™
Product type: Secondary Packaging
Date of launch: 13/01/20
Current development phase: Commercialization
Patent: Ongoing
Target markets: 503A & 503B Pharmaceutical compounders
Target clients: Pharmaceutical companies
Business model: Direct sales

FACT SHEET

PRODUCT DESCRIPTION

The SyringeLok™ Tamper Evident Caps allows for visual confirmation if a drug, or other syringe contents have been tampered with, or exposed to the environment prior to administration.

APPLICATION AREAS

Syringes

KEY FEATURES (USP)

- Designed and Packaged for high-speed automated syringe filling lines
- Available in bulk sterile and bulk non-sterile packaging
- Clear plastic for laser guidance automated assembly
- Available for private label with laser engraving
- 510k Clearance (Pending)
- CE Mark (Pending)
- USP Class VI animal derivative free materials
- Class 8 clean room molded
- ISO 13485 & FDA Registered manufacturer
- Compliance REACH & ROHS
- Gamma & e-beam stable
- Compatibility with ISO 80369-7 and ISO594-compliant luers

Website: https://www.nordsonmedical.com/Components-and-Technologies/Fluid-Management-Components/Tamper-Evident-Caps/

PATIENT SUPPORT APP

2020

Company name: Rondo AG

Country: Switzerland

Product name: Patient Support App

Product type: Secondary Packaging

Date of launch: 01/07/19

Current development phase: Commercialization

Patent: None

Target markets: Europe

Target clients: Pharmaceutical companies

PHARMAPACK AWARDS WINNER 2020

FACT SHEET

PRODUCT DESCRIPTION

The Rondo Augmented Reality App merges the physical and digital worlds. The intelligent pharmaceutical packaging serves as a communication medium with the patients and offers them a gateway to valuable information and services of the digital world. Rondos modular Patient Support App focuses on solutions that address patient needs and increase patient adherence. The app can be used for both clinical trials and commercial products and is available on IOS and Android. With the Patient Support App you can simplify the patient's life.

APPLICATION AREAS

The Patient Support App gives you the opportunity to get closer to your patients:

- You will have the opportunity to share information about different products and in addition tell a story about the company.
- Within the Patient Support App, the artwork of your packaging stays the same, even when you change the content of the App
- The app is available for Android and IOS.
- The Patient Support App can be used on smartphones in connection with wearables.

KEY FEATURES (USP)

- Increase patient adherence

  Never miss an appointed time again: A reminder function makes it easier for patients to keep to their individual medication plan. This leads to greater adherence to medication, which leads to better chances of recovery - and more robust results in clinical trials.

- Digital leaflet with "Text to speech" function

  The difficult reading of narrow printed leaflets is no longer necessary. With the Patient Support App, users can read all essential information on their smartphone - or have it read aloud using the "Text to Speech" function.

- Patient instructions by video

  Pictures are often more understandable than info texts or explanations by experts. The app can therefore also include videos demonstrating to users how to use drugs or syringes correctly.

Website: https://www.rondo-packaging.com/de/pharma-40/

QUAZAR®

2020



Company name: SICPA
Country: Switzerland
Product name: QUAZAR®
Product type: Secondary Packaging
Date of launch: 2019
Current development phase: Commercialization
Patent: Confidential
Target markets: Worldwide
Target clients: Pharmaceutical companies
Business model: Direct sales to brand owners

FACT SHEET

PRODUCT DESCRIPTION

QUAZAR® is SICPA's newest innovative overt solution for strategic product branding and protection delivered in the form of a unique security label. This innovative overt security feature is characterised by visually-engaging effects and is easy to authenticate by tilting. Based on patented and proprietary technologies and a fully controlled supply chain, QUAZAR® is highly resilient to counterfeiting.

APPLICATION AREAS

Security labels for businesses requiring the most exclusive secure labels, and for all premium or high-risk brands and products. Application on security labels for Pharma packaging.

KEY FEATURES (USP)

UNIQUE, ULTIMATE SECURITY SOLUTION

- Strong visual impact
- Easy to authenticate
- Robust resistance against counterfeiting
- Proprietary technologies with intellectual property protection
- Fully controlled supply chain from materials to label printing equipment
- Dedicated design and integration services
- Fully customisable label creation
- Flexibility to integrate company logos and brand design specifications
- Versatility on a wide range of substrates and applications
- Proven success in brand-specific and industry-specific applications.

Website: https://brandprotection.sicpa.com/

QUANTIFEEL QUALITY ASSURANCE PLATFORM

2020

Company name: Schott - Smart Skin Technologies

Country: Canada

Product name: Quantifeel Quality Assurance Platform

Product type: Machinery

Date of launch: 03/06/19

Current development phase: Commercialization

Patent: 88,849,139,488,538

Target markets: North America, Europe

Target clients: Pharmaceutical companies

Business model: Direct sales

PHARMAPACK AWARDS WINNER 2020

FACT SHEET

PRODUCT DESCRIPTION

Quantifeel provides a replica sensor that travels through the filling line/ packaging line along with other containers. Innovative solution for monitoring forces and impacts on packaging lines that allow operators to identify areas on the line that are causing damage, fix them and verify the improvement.

APPLICATION AREAS

This product is used on filling lines, conveyors, inspection equipment.

KEY FEATURES (USP)

Each sensor has dozens, maybe hundreds of sensors depending on the size. Ability to measure pressure, impact, rotation and tilt. Each data stream is useful to troubleshoot issues on the line that could be causing quality issues on the line.

Website: https://smartskintech.com/en/products/pharma

FLEXILINE

2020

Company name: Technic Automation
Country: France
Product name: Flexiline
Product type: Machinery
Date of launch: 02/09/19
Current development phase: Commercialization
Patent: None
Target markets: World
Target clients: Pharmaceutical companies
Business model: Direct sales

FACT SHEET

PRODUCT DESCRIPTION

Modular syringe assembly machine of 4 different sizes to be integrated in an ISO 7 clean room. It is carried out in compliance with the norm 21 CFR Part 11 especially following the GAMP5 protocol, the design specifications(FDS, HDS and SDS) and according to validation and qualification protocols (FAT,SAT,QI and QO).

Conformity checks of all the products at each assembly steps combined with all events traceability guarantee a monitored and controlled production.

APPLICATION AREAS

This machine is a perfect illustration of the know- how of Technic Automation:

- A robust and comprehensive design including the latest technology
- An optimized realization made with long-term, strong and trusted partners
- A detailed technical documentation up to the pharmaceutical standard
- An integration in clean room up to ISO 5
- A technical participation in machine validations and qualifications according to protocols developed in partnership with the customer
- A strong support up to the production start and after what makes Technic automation a solid partner to design, manufacture and install every kind of medical device assembly machine in clean room environment.

KEY FEATURES (USP)

An adaptive and modular assembly machine to meet with a wide variety of customer products. Using 4 independent feeders can afford flexible production performance and an easy integration of new potential components to be assembled. Syringes transfer with intelligent conveyors and robots, all driven with a precise and repeatable industrial IT ensures products integrity. Vision systems are located at the most sensitive machine positions to ensure a 100% compliance control of products without impacting productivity.

Finally, the intuitive and customized user interfaces offer the opportunity to create new production recipes or new visions models. They also guarantee transparency and traceability of process and product parameters.

Website: http://www.technic-automation.fr/Medical.html?PHPSESSID=5u4vndek87bpr459r9cegoh4b5

Demo video: https://ubm.box.com/s/jyifih3zxkqh3lbkqcogg711e05bfmk1